1	Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine
2	$(\mbox{Covovax}^{\mbox{TM}})$ after homologous and heterologous two-dose regimens
3	Sitthichai Kanokudom ^{a,b} , Jira Chansaenroj ^a , Nungruthai Suntronwong ^a , Suvichada Assawakosri
4	^{a,b} , Ritthideach Yorsaeng ^a , Pornjarim Nilyanimit ^a , Ratchadawan Aeemjinda ^a , Nongkanok
5	Khanarat ^a , Preeyaporn Vichaiwattana ^a , Sirapa Klinfueng ^a , Thanunrat Thongmee ^a , Apirat
6	Katanyutanon ^c , Wichai Thanasopon ^c , Jirawan Arayapong ^d , Withak Withaksabut ^c , Donchida
7	Srimuan ^a , Thaksaporn Thatsanatorn ^a , Natthinee Sudhinaraset ^a , Nasamon Wanlapakorn ^a ,
8	Sittisak Honsawek ^{b,*} and Yong Poovorawan ^{a,e,*}
9	^a Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University,
10	Bangkok, 10330, Thailand.
11	^b Center of Excellence in Osteoarthritis and Musculoskeleton, Faculty of Medicine,
12	Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society,
13	Bangkok, 10330, Thailand.
14	^c Chonburi Provincial Public Health Office, Bansuan, Mueang Chonburi, Chonburi, 20000,
15	Thailand.
16	^d Chonburi Hospital, Bansuan, Mueang Chonburi, Chonburi, 20000, Thailand.
17	^e FRS(T), the Royal Society of Thailand, Sanam Sueapa, Dusit, Bangkok, 10300, Thailand.
18	
19	Corresponding authors: Sittisak Honsawek (sittisak.h@chula.ac.th); Yong Poovorawan
20	(yong.p@chula.ac.th)

- 21 Running head: Third booster dose with COVID-19 protein subunit vaccine

2

23 Abstract

Objective: To report the safety and immunogenicity profile of a protein subunit vaccine
 (CovovaxTM) given as a third (booster) dose to individuals primed with different primary vaccine
 regimens.

Methods: Individuals primed with two doses of COVID-19 vaccines for at least 3 months were 27 enrolled and assigned to five groups according to their primary vaccine regimens: CoronaVac, 28 BBIBP-CorV, AZD1222, BNT162b2, and CoronaVac/AZD1222. Immunogenicity analysis was 29 30 performed to determine binding antibodies, neutralizing activity, and the T-cell response. **Results:** Overall, 215 individuals were enrolled and boosted with the CovovaxTM vaccine. The 31 32 reactogenicity achieved was mild-to-moderate. Most participants elicited a high level of binding 33 and neutralizing antibody responses against wild type and omicron variants following the booster dose. The 197 participants were classified by anti-N IgG. Of these, 141/197 (71.6%) were a 34 seronegative population, and neutralizing activity and IFN-y release were further monitored. A 35 booster dose could elicit neutralizing activity to wild type and omicron variants by more than 36 95% and 70% inhibition at 28 days, respectively. The CovovaxTM vaccine could elicit a cell-37 38 mediated immune response. **Conclusion:** The protein subunit vaccine (CovovaxTM) can be proposed as a booster dose after 39 two different priming dose regimens. It has strong immunogenicity and good safety profiles. 40

41

Keywords: Severe acute respiratory virus 2 (SARS-CoV-2); Omicron; side effect; CovovaxTM;
Novavax; booster dose

3

45 **1. Introduction**

46	The omicron variant (B.1.1.529) of severe acute respiratory virus 2 (SARS-CoV-2) was
47	first identified in November 2021 (Viana et al., 2022) and has dramatically increased the
48	transmission of Coronavirus disease 2019 (COVID-19) globally. Consequently, several vaccines
49	targeting the SARS-CoV-2 spike (S) protein have been developed. The COVID-19 vaccine
50	protects against serious diseases, hospitalizations, and death. However, vaccination does not
51	entirely prevent infection and transmission to others. Massive two-dose vaccination campaigns
52	cannot control breakthrough infections caused by the variants (Cele et al., 2022, Kuhlmann et al.,
53	2022). A third dose is recommended to obtain high immunity against the omicron variant and its
54	subvariants. In Thailand, several forms of COVID-19 vaccines have been introduced, including
55	inactivated vaccines (CoronaVac, BBIBP-CorV), viral vectored vaccines (AZD1222), and
56	mRNA vaccines (BNT162b2), which have resulted in the population receiving two-dose (prime)
57	series of the vaccine. Several two-primed vaccine regimens have been widely used and
58	approved. Previous studies have shown that booster doses of homologous and heterologous
59	regimes achieved a high level of antibody titers (Munro et al., 2021, Wanlapakorn et al., 2022a)
60	and are associated with strong protection against the omicron variant (Guirakhoo et al., 2022).
61	Evidence has also indicated that the booster dose improved vaccine effectiveness and reduced
62	severe outcomes of COVID-19 (Grewal et al., 2022).
63	On 21 April 2022, the Quadrilateral Security Dialogue donated 200,000 of doses
64	Covovax TM (Serum Institute of India (SII) Pvt Ltd, Pune, India) to Thailand. This vaccine, also

65 known as Novavax vaccine (NVX-CoV2373/ NuvaxovidTM) (Novavax, Inc., Gaithersburg, MD,

66 USA) is manufactured under the brand name CovovaxTM. CovovaxTM is a protein subunit

67 vaccine to prevent COVID-19.

4

Protein subunit vaccines have been used for decades to prevent viral infectious diseases. 68 To date, recombinant protein subunit vaccines have emerged as candidate vaccines. This 69 vaccine, along with the adjuvant, can directly elicit protective immune responses. The protein 70 subunit vaccine, which derives from a more traditional technology, may appear to have lower 71 side effects in this setting, although this remains to be seen. Moreover, protein subunit vaccines 72 73 present additional benefits than the viral vector and mRNA vaccines because as they overcome the limitations due to storage conditions and is easier to ship to rural/remote areas (Bhiman et al., 74 75 2022; Fiolet et al., 2022).

76 The United States Food and Drug Administration (US-FDA) has recently authorized the Novavax protein subunit vaccine for primary series vaccination of recipients aged 12 years and 77 older (US-FDA. 2022). A phase 3 trial in the United Kingdom demonstrated that two doses of 78 Novavax showed an efficacy of 86.3% against the alpha variant and 96.4% against other variants 79 that circulated between September and November 2021 (Heath et al., 2021). Furthermore, the 80 81 United States and Mexico demonstrated 90% efficacy against symptomatic and 100% efficacy against severe COVID-19 (Dunkle et al., 2022). However, this vaccine has not been authorized 82 to be used as a booster dose in the United States. Recently, the COV-Boosted trial in the United 83 84 Kingdom investigated the booster effect of the Novavax vaccine in two-dose individuals primed with AZD1222 and BNT162b2. The results showed that a high level of anti-Spike IgG could be 85 86 detected in AZD1222 and BNT162 primed individuals, and neutralizing antibody against the 87 wild type and delta variant was also evident (Munro et al., 2021). However, information is limited on the use of the COVID-19 protein subunit vaccine as the third booster dose following 88 89 vaccination with different platforms and schedules, especially in combination with a series of 90 inactivated vaccine. This study investigated the reactogenicity and immunogenicity of the protein

5

91	subunit COVID-19 vaccine Covovax TM (Serum Institute of India Pvt Ltd, Pune, India) as a third
92	dose (booster dose) subsequent to a two-dose primary series COVID-19 vaccine.

93 **2. Materials and methods**

94 2.1. Study design and participants

The cohort study was conducted between May and July 2022 at the Center of Excellence
in Clinical Virology, Chulalongkorn University, Bangkok, and 10 vaccination sites in Chonburi
province. The study protocol was approved by the Institutional Review Board (IRB) of the
Faculty of Medicine of Chulalongkorn University (IRB 871/64) and was performed under the
principles of the Declaration of Helsinki. This trial was registered in the Thai Clinical Trials
Registry (TCTR 20210910002). Written informed consent was obtained from participants prior
to enrollment.

A total of 215 healthy adults 18 years and older, who had previously been immunized with any two doses of COVID-19 vaccine for at least 3 months, were enrolled. The cohorts were assigned five groups according to their primary vaccine series, including homologous and heterologous regimens. All participants with no history of COVID-19 disease were reactivated with CovovaxTM as a booster dose.

Patients were classified into five groups based on the priming vaccine regimen received: two doses of CoronaVac (hereafter referred to SVC), two doses of BBIBP-CorV (hereafter referred to SPC), two doses of AZD1222 (hereafter referred to AZC), two doses of BNT162b2 (hereafter referred to PFC), and heterologously primed with CoronaVac/AZD1222 (hereafter referred to SAC). Blood samples were collected before vaccination (day 0, baseline) and after the booster dose (day 14 ± 7 and day 28 ± 7). The sera samples were subjected to laboratory

113	evaluation. Twelve participants were excluded from the analysis for the following reasons: in
114	two participants the baseline anti-RBD Ig levels were unreliable (18,877 and 15,479 U/mL) and
115	the baseline anti-nucleocapsid IgG (anti-N IgG) was negative, while 10 participants were no
116	longer able to continue with the project.
117	We selected anti- N IgG for baseline specimens and divided subjects into seronositive
11/	we selected and 141gG for busenile specificity and divided subjects into scropositive
118	and serone gative anti-N IgG groups. Participants who had seropositive anti-N IgG (\geq 1.4) before
119	and after vaccination were classified into previous infection and breakthrough infection,
120	respectively. In contrast, individuals who had seronegative anti-N IgG were further assessed for
121	immune responses, as described in Figure 1.
122	2.2. Vaccine used as a booster dose
123	Covovax TM was used as a booster dose in this trial. One dose (0.5 mL) contains 5 μ g of
124	SARS-CoV-2 recombinant Spike Protein (Prototype Wuhan) with 50 µg Matrix-M1 [™] adjuvants
125	(Serum Institute of India, 2022).
126	2.3. Safety assessments
127	The participants self-reported reactogenicity using an electronic or paper questionnaire,
128	starting on the day of vaccination and for 7 subsequent days (days 0-7). Local, systemic, and
129	adverse events (AE) were classified as mild, moderate, and severe, as previously described
130	(Kanokudom et al., 2022).
131	2.4. Laboratory assessments
132	Serum samples were collected to determine binding antibody responses, including total
133	immunoglobulin (Ig) anti-RBD of the SARS-CoV-2 spike protein (the anti-RBD Ig), the anti-

7

134	RBD IgG, and anti-N IgG as previously described (Kanokudom et al., 2022). Neutralizing
135	activities against wild type (Euroimmun, Lubeck, Germany) and omicron (BA.2) (GenScript
136	Biotech, NJ, USA) were analyzed using a surrogate virus neutralization test (sVNT) as
137	previously described (Assawakosri et al., 2022b, Wanlapakorn N. et al., 2022b). The
138	seropositivity of sVNT against wild type and omicron (BA.2) showed \geq 35% and \geq 30%
139	inhibition, respectively. The interferon-gamma (IFN- γ) release assay measuring the T cell
140	response to SARS-CoV-2 to Antigen 3 was performed using a heparinized whole blood sample.
141	An elevated response was defined as a value of at least 0.20 IU/mL greater than the negative
142	control (Nil), which was used to subtract IFN- γ release not deriving from SARS-CoV-2-specific
143	T cell stimulation (Busà et al., 2022).

144 2.5. Statistical analysis

The sample size was calculated using the G* power software version 3.1.9.6 (based on conventional effect size = 0.25, given significance level (α) = 0.05, power (1- β) = 0.8, numerator degree of freedom = 3, and number of groups = 4). The calculated total sample was 179. Therefore, the desired enrolled sample with 10% dropout coverage is approximately 200 (n=50/group).

Categorical analyses of age and sex were performed using Pearson's Chi-square test.
Anti-RBD Ig and IgG were designated as geometric mean titers (GMT) with a 95% confidence
interval (CI). sVNT and IFN-γ values are presented as medians with interquartile ranges (IQR).
The geometric mean ratio (GMR) of anti-RBD Ig/IgG was calculated using SPC as the referent
group. Significant differences between groups in antibody titers and percentage inhibition were
calculated by ANCOVA with Bonferroni's adjustment. High IFN-γ values (IU/mL minus Nil)

8

was evaluated using the Mann–Whitney U test. A p-value of <0.05 was considered statistically significant.

158 **3. Results**

159 3.1 Demographic data and baseline characteristics

A total of 215 participants were enrolled to receive CovavaxTM as a booster dose. 160 161 According to their primary vaccine regimens, participants were classified into five groups: SVC (n=5), SPC (n=50), AZC (n=55), PFC (n=51), and SAC (n=54). The sample size of the SVC 162 163 group was insufficient to conduct the statistical analysis (n=5). Hereafter, only four groups were considered for the statistical analysis. The number of women per total (%) participants was 2/5 164 165 (40.0%), 21/50 (42.0%), 29/55 (52.7%), 28/51 (54.9%), and 23/54 (42.6%), respectively. The 166 mean age (SD) of the participants was 42.0 (11.2), 39.3 (12.3), 49.7 (14.6), 42.0 (18.7), and 37.7 (13.9), respectively. All participants presented a good healthy profile observed by the physician 167 (well-control comorbidities were permitted) as described in Table 1. The mean (SD) of the 168 interval between doses 2 and 3 was 367 (22.3), 236.3 (32.5), 218.9 (37.6), 185.5 (64.8), and 169 235.3 (31.2) for each respective group. The blood sample was collected 2 and 4 weeks after 170 171 vaccination, as described in Table 1. The sex of the participants and the duration of blood collection were comparable, while the age and the interval between doses 2 and 3 showed 172 significant differences. 173

In parallel, a subgroup of participants was investigated and classified by baseline anti-N
IgG level (day 0). All participants were divided into two populations, including the seronegative
(n=141) and seropositive (n=62) anti-N IgG populations. Participants (n=6) who received a
breakthrough infection (defined by anti-N IgG levels) were excluded from the subgroup analysis.

9

178	Thus, the number of participants (seronegative: seropositive) were 5:0, 31:16, 34:12, 37:10, and
179	34:18 for the SVC, SPC, AZC, PFC, and SAC groups, respectively. The demographics and
180	characteristics of the categorized participants are shown in Table 2.

181 3.2 A safety and tolerability profile

Profiles of grades of local and systemic reactions within 7 days after CovovaxTM 182 vaccination in each primed group had similar incidences (Supplementary Figure S1A–D). A total 183 of 202 of 215 participants experienced a few adverse events. Adverse events were commonly 184 185 observed as injection site pain (33.7%) rather than myalgia (21.3%), headache (11.8%), and 186 redness (8.9%). In addition, other adverse events were observed to be less than 7% and well tolerated within a few days (Figure 2). One participant in the SVC regimen reported severe 187 188 injection site pain and headache after the booster dose. None of the participants reported serious adverse events. 189

3.3 Anti-RBD Ig/IgG responses of all enrolled participants, negative anti-N IgG participants, andsubgroup analysis

Overall, antibody responses were detected in all participants who received the 192 CovovaxTM vaccine. There were significant differences in anti-RBD Ig GMTs between all 193 groups compared to those receiving SPC at baseline. Before vaccination, the GMTs of the anti-194 RBD Ig of each of the five groups SVC, SPC, AZC, PFC, and SAC were 17.1, 72.6, 623.5, 1386, 195 and 674.8 U/mL, respectively. Consequently, the GMT of the anti-RBD Ig at 14 days after a 196 booster dose was 18,626, 14,071, 8745, 9539 and 11,286 U/mL for the SVC, SPC, AZC, PFC, 197 198 and SAC groups, respectively. Subsequently, anti-RBD Ig levels were reduced slightly to 14,410, 9119, 6868, 8564, and 8488 U/mL at 28 days, respectively. The anti-RBD Ig of SPC was 199

10

200	significantly higher than AZC, while other groups were comparable at 28 days postvaccination
201	(Figure 3A and Supplementary Table S1). Similar trends were observed with anti-RBD IgG
202	levels (Figure 3B and Supplementary Table S1). However, anti-RBD IgG titers of the SPC group
203	were significantly higher than those of the other three groups at 28 days.
204	Based on the baseline anti-RBD Ig/IgG titers (Figure 3A-B), participants could be
205	stratified into two populations. This population could be further classified based on anti-N IgG
206	results. Overall, 141/197 (71.6%) individuals were seronegative for anti-N IgG (< 1.40 S/C).
207	Here, we further analyzed the anti-RBD Ig/IgG titers of seronegative participants for anti-N IgG,
208	as indicated in Figure 3C,D. The baseline GMTs of anti-RBD Ig were 17.1, 13.7, 276.2, 759.6,
209	and 186.7 U/mL for the respective groups. At baseline, the GMT of anti-RBD Ig was
210	significantly lower in the SPC group compared to others. At 14 days, the GMTs of anti-RBD Ig
211	were 18626, 15149, 7627, 7846, and 10494 U/mL, respectively and consequently, the anti-RBD
212	IgG levels were slightly reduced to 14410, 9270, 5735, 7032, and 7865 U/mL at 28 days,
213	respectively. Furthermore, comparable anti-RBD IgG levels were determined for all groups
214	except for those receiving SPC, whose titers showed a significant difference (Figure 3C and
215	Supplementary Table S1). Moreover, a similar response was observed anti-RBD IgG levels
216	(Figure 3C and Supplementary Table S1).
217	In total, 192 individuals receiving SPC, AZC, PFC, and SAC vaccines were classified by
218	subgroup analysis according to the baseline anti-N IgG levels. Five individuals receiving SVC
219	were not included in the calculation. The anti-RBD Ig levels between seronegative and
220	seropositive anti-N IgG populations was compared. At baseline, the anti-RBD Ig of the
221	seropositive population in all groups was significantly higher than that of the seronegative

population. After a booster dose, the anti-RBD Ig of the SPC and SAC regimens showed a

223	significant difference between populations (Supplementary Figures S2A,D). In contrast, there
224	was no significant difference in AZC and PFC regimens (Supplementary Figure S2B,C).
225	3.4 Neutralizing activity against wild type and omicron BA.2 using sVNT
226	At baseline, the number of seropositive neutralizing activities against the wild type
227	SARS-CoV-2 strain following SVC, SPC, AZC, PFC, and SAC regimes were 0/10, 0/10, 7/10,
228	8/10, and 2/10, respectively (Figure 4A and Supplementary Table S1). Nonetheless, some
229	seropositive neutralizing activities against the BA.2 omicron variant of the respective groups
230	were also detected in 0/10, 0/10, 1,10, 7/10 and 0/10, respectively (Figure 4B and Supplementary
231	Table S1).
232	At day 28 after a booster dose, all boosted participants showed restored neutralizing
233	activity against the wild type by more than 95% inhibition, reaching the upper limit of an assay
234	(Figure 4A). The neutralizing activity against the omicron BA.2 variant in participants achieved
235	marked inhibitory activity as indicated by the 92.1%, 83.5%, 70.1%, 81.3%, and 82.6% values
236	corresponding to SVC, SPC, AZC, PFC, and SAC, respectively. Only two participants showed
237	no seroconversion of neutralizing activity against omicron BA.2. Furthermore, the percentage
238	inhibition against BA.2 omicron variant in all regimens was comparable (Figure 4B).
239	3.5 Total IFN- γ release induced by the Ag3 QFN assay
240	The T-cell response was assessed by measuring total IFN- γ release in whole blood
241	samples of participants who received a booster dose. At baseline, the remaining IFN- γ level of
242	IFN- after the second dose was less than 0.2 IU/mL for all participants. The results showed that
243	the IFN-y level after vaccination of all participants was significantly increased at 14 days and
244	slightly reduced at the 28-day follow-up except for those receiving the SAC regime. The group

12

comparison indicated that the IFN- γ level was comparable at 14 and 28 days (Figure 5). The elevated response at 14 days was 5/5 (100%), 19/21 (90.4%), 18/21 (85.7%), 17/24 (70.8%), and 18/22 (81.8%) for the respective groups.

248 **4. Discussion**

Herein, we report the first study evaluating responses to the CovovaxTM protein subunit 249 250 vaccine as a booster dose in individuals who had received two-dose vaccination (priming) with 251 either homologous inactivated or heterologous inactivated/viral vector vaccine regimens. The 252 reactogenicity and immunogenicity of the protein subunit vaccine. The recruitment criteria were no history of COVID-19 infection. The enrolled participants included a seropositive anti-N IgG 253 254 population of approximately 30% during the study period (May 2022 to July 2022). Individuals 255 with a positive anti-N IgG may have experienced an infection leading to asymptomatic or mild disease. The adverse events record revealed common effects were injection site pain, myalgia, 256 257 headache, and redness at the injection site. A few incidences of adverse effects were observed but were assessed as mild-to-moderate in severity. The adverse events reported herein were 258 similar to those of pain, myalgia, and headache described in a previous Novavax study from 259 Australia (Keech et al., 2020, Mallory et al., 2022) and the United States (Mallory et al., 2022). 260 Furthermore, our findings demonstrated that the CovovaxTM vaccine elicited fewer adverse 261 events compared to the viral vector or the mRNA-COVID-19 vaccine (Assawakosri et al., 2022a, 262 263 Fiolet et al., 2022, Munro et al., 2021). Furthermore, the adverse effects following vaccination differed based on the booster vaccine administered. There was no correlation with the history of 264 the previous vaccine. 265

Before receiving booster doses, the anti-RBD Ig/IgG titer in immunized participants was
notably lower. The anti-RBD Ig and IgG responses after boost indicated that the levels of

13

268	binding antibodies were significantly increased regardless of the primary series vaccine regimen
269	received. Our study found that the Covovax TM vaccine was suitable for use as a booster dose.
270	Consistent with a previous study (Munro et al., 2021), the Novavax subunit protein vaccine
271	could elicit a high antispike protein IgG titer in individuals who had received two doses of
272	AZD1222 or BNT162b2.

273	Compared to previous studies evaluating three doses of vaccination in healthy adults, we
274	observed that using the Covovax TM vaccine in the primary series of the inactivated vaccine group
275	achieved higher antibody levels than three doses of the inactivated vaccine (Ai et al., 2022,
276	Assawakosri et al., 2022b). Furthermore, a heterologous booster dose including Covovax TM in
277	the primary series of viral vector vaccine (AZD1222) achieved a robust immune response
278	compared to three doses of AZD1222 (Assawakosri et al., 2022a). However, a heterologous
279	booster dose with Covovax TM in individuals receiving a primary series of BNT162b2 showed a
280	lower immune response compared to three doses of BNT62b2 (Wanlapakorn et al., 2022a).
281	Notably, multiple factors, such as sex, age, and duration after the primary series, might have
282	interfered with the analysis of the booster effect.

Consistent with the anti-RBD Ig and IgG responses observed in this study, the booster dose elicited a high immune response and neutralizing activity against wild type and omicron BA.2 variants of SARS-CoV-2. However, neutralizing antibodies against the omicron variant were slightly lower than that toward the prototype variant (Bhiman et al., 2022). Several mutations in the RBD could alter the binding affinity of antibodies produced from wild type vaccines (Cao et al., 2022). The present study observed IFN-γ releasing after 14 days among all regimens. In agreement with previous studies, the protein subunit vaccine and Matrix-M1

14

290	adjuvant could induce high levels of cellular immunity (Keech et al., 2020, Tian et al., 2021).
291	Besides the humoral response, the Covovax TM vaccine could elicit a robust cellular response.
292	The Com-COV trial in the United Kingdom examined sera for anti-N IgG levels at
293	baseline and used seropositivity to define SARS-CoV-2 infection (Lui et al., 2021). Nearly one-
294	third of the participants were suspected of exposure to SARS-CoV-2 infection prior to
295	enrollment. These individuals were associated with asymptomatic infection or mild/transient
296	symptoms, indicating an underestimate of SARS-CoV-2 infection (Tande et al., 2022). The
297	subgroup analysis may suggest that both seronegative and seropositive anti-N IgG levels
298	enhanced the anti-RBD Ig titer as seen in the AZC and PFC groups. In contrast, differences in
299	the SPC and SVC vaccinated groups were statistically significant. Furthermore, participants in
300	this study had experienced SARS-CoV-2 infection within a few weeks of sampling, despite
301	having received booster vaccination.
302	Our study was subject to certain limitations. First, the SCV group contained a lower
303	number of participants due to Thailand's enacting of a massive CoronaVac vaccination campaign
304	since April 2021, which has diminished further after mRNA vaccines were implemented in
305	September 2021. This population had received a third dose of another vaccine to address the
306	third and subsequent waves of the SARS-CoV-2 endemic. Furthermore, the surrogate virus
307	neutralization test against the wild type reached the upper limit of >95% inhibition (Kanokudom
308	et al., 2022). The pseudovirus reduction neutralization test will be used in future to overcome
309	these limitations. Additionally, we were unable to obtain the results of COVID-19 testing of the
310	seropositive anti-N IgG population to establish their history of SARS-CoV-2 infection.

312 **5.** Conclusions

313	The protein subunit vaccine as a booster dose is safe and elicits a high level of binding
314	and neutralizing antibodies against SARS-CoV-2, as well as a good cellular response. Thus, the
315	Covovax TM vaccine can be recommended for use as a booster in individuals receiving variable
316	primary vaccine regimens. Our data indicate the Covovax TM vaccine will be beneficial and
317	convenient as a heterologous booster dose and will be of value for public health vaccine
318	implementation guidelines.
319	Acknowledgments: We would like to thank all Center of Excellence in Clinical Virology
320	personnel and all participants for contributing to and supporting this project. This research was
321	financially supported by the Health Systems Research Institute (HSRI), National Research
322	Council of Thailand (NRCT), the Center of Excellence in Clinical Virology, Chulalongkorn
323	University, and King Chulalongkorn Memorial Hospital, and partially supported by the Second
324	Century Fund (C2F) of Sitthichai Kanokudom, Chulalongkorn University.
325	Author Contributions: Conceptualization, S.K. (Sitthichai Kanokudom), P.N., S.H. and Y.P.;
326	data curation, S.K. (Sitthichai Kanokudom), R.Y., N.S. (Nungruthai Suntronwong), S.A., A.K.,
327	W.T., J.A., W.W., D.S., T.T. (Thaksaporn Thatsanatorn), N.S. (Natthinee Sudhinaraset) and
328	N.W.; formal analysis, S.K. (Sitthichai Kanokudom); methodology, S.K. (Sitthichai
329	Kanokudom), J.C., R.A., N.K., P.V., S.K. (Sirapa Klinfueng) and T.T (Thanunrat Thongmee);
330	project administration, Y.P.; writing-original draft, S.K. (Sitthichai Kanokudom); writing-
331	review and editing, S.K. (Sitthichai Kanokudom), S.H. and Y.P. All authors have read and

agreed to the published version of the manuscript.

333	Funding: This research was financially supported by the Health Systems Research Institute					
334	(HSRI), National Research Council of Thailand (NRCT), the Center of Excellence in Clinical					
335	Virology, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, and partially					
336	supported by the Second Century Fund (C2F) of Sitthichai Kanokudom, Chulalongkorn					
337	University.					
338	Institutional Review Board Statement: The study protocol was approved by the Institutional					
339	Review Board (IRB), Faculty of Medicine, Chulalongkorn University (IRB number 871/64).					
340	Informed Consent Statement: Informed consent was obtained before participant enrollment.					
341	The study was conducted according to the Declaration of Helsinki and the Good Clinical Practice					
342	Guidelines (ICH-GCP) principles.					
343	Data Availability Statement: The datasets generated and analyzed during the current study are					
344	available from the corresponding author upon reasonable request.					
345	Conflicts of Interest: The authors declare no conflict of interest.					
346	References					
347	Ai J, Zhang Y, Zhang H, Zhang Q, Fu Z, Lin K, et al. Safety and immunogenicity of a third-dose					
348	homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-					
349	label study. Emerg Microbes Infect. 2022;11(1):639-47.					
350	Assawakosri S, Kanokudom S, Chansaenroj J, Suntronwong N, Auphimai C, Nilyanimit P, et al.					
351	Persistence of immunity against Omicron BA.1 and BA.2 following homologous and					
352	heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222					
353	vaccination. Int J Infect Dis 2022a;122:793-801.					

354	Assawakosri S, Kanokudom S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, et
355	al. Neutralizing Activities against the Omicron Variant after a Heterologous Booster in
356	Healthy Adults Receiving Two Doses of CoronaVac Vaccination. J Infect Dis
357	2022b:jiac092.
358	Bhiman JN, Richardson SI, Lambson BE, Kgagudi P, Mzindle N, Kaldine H, et al. Novavax
359	NVX-COV2373 triggers potent neutralization of Omicron sub-lineages. bioRxiv 2022.
360	https://doi.org/10.1101/2022.07.14.500148.
361	Busà R, Sorrentino MC, Russelli G, Amico G, Miceli V, Miele M, et al. Specific Anti-SARS-
362	CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-
363	BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System
364	Components. Front Immunol. 2022;13:856657.
365	Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, et al. Omicron escapes the majority of
366	existing SARS-CoV-2 neutralizing antibodies. Nature 2022;602(7898):657-63.
367	Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, et al. Omicron extensively
368	but incompletely escapes Pfizer BNT162b2 neutralization. Nature 2022;602(7898):654-6.
369	Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, et al. Efficacy
370	and Safety of NVX-CoV2373 in Adults in the United States and Mexico. N Engl J Med
371	2022;386(6):531-43.
372	Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19
373	vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and
374	variants of concern: a narrative review. Clin Microbiol Infect 2022;28(2):202-21.

375	Grewal R, Kitchen SA, Nguyen L, Buchan SA, Wilson SE, Costa AP, et al. Effectiveness of a
376	fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care
377	residents in Ontario, Canada: test negative design study. BMJ 2022;378:e071502.
378	Guirakhoo F, Wang S, Wang CY, Kuo HK, Peng WJ, Liu H, et al. High Neutralizing Antibody
379	Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and
380	BA.2 After UB-612 Vaccine Booster. J Infect Dis. 2022:jiac241.
381	Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and Efficacy of
382	NVX-CoV2373 Covid-19 Vaccine. N Engl J Med 2021;385(13):1172-83.
383	Kanokudom S, Assawakosri S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, et
384	al. Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector,
385	and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated
386	Vaccine. Vaccines (Basel) 2022;10(1):86.
387	Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1-2 Trial of a SARS-CoV-2
388	Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med 2020;383(24):2320-32.
389	Kuhlmann C, Mayer CK, Claassen M, Maponga T, Burgers WA, Keeton R, et al. Breakthrough
390	infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. The Lancet
391	2022;399(10325):625-6.
392	Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and
393	immunogenicity of heterologous versus homologous prime-boost schedules with an
394	adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind,
395	randomised, non-inferiority trial. The Lancet 2021;398(10303):856-69.
396	Mallory RM, Formica N, Pfeiffer S, Wilkinson B, Marcheschi A, Albert G, et al. Safety and
397	immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant

- 398 spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-
- controlled, phase 2 trial. Lancet Infect Dis 2022.
- 400 Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and
- 401 immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two
- doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded,
- 403 multicentre, randomised, controlled, phase 2 trial. Lancet 2021;398(10318):2258-76.
- 404 Tande AJ, Pollock BD, Shah ND, Farrugia G, Virk A, Swift M, et al. Impact of the Coronavirus
- 405 Disease 2019 (COVID-19) Vaccine on Asymptomatic Infection Among Patients
- 406 Undergoing Preprocedural COVID-19 Molecular Screening. Clin Infect Dis
- 407 2022;74(1):59-65.
- 408 The United States-Food and Drug Administration (US-FDA). Novavax Letter of Authorization
- 409 08192022 FDA. Date updated 19 August 2022. Available from:
- 410 https://www.fda.gov/media/159902/download (accessed 6 September 2022).
- 411 Tian JH, Patel N, Haupt R, Zhou H, Weston S, Hammond H, et al. SARS-CoV-2 spike
- 412 glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection
- 413 in mice. Nat Commun 2021;12(1):372.
- 414 Serum Institute of India. SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein
- 415 Nanoparticle Vaccine (CovovaxTM). Date updated June 2022. Available from:
- 416 https://www.seruminstitute.com/pdf/COVOVAX_Insert.pdf. (accessed 6 September 2022).
- 417 Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid epidemic
- 418 expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature
- 419 2022;603(7902):679-86.

420	Wanlapakorn N, Suntronwong N, Kanokudom S, Assawakosri S, Nilyanimit P, Yorsaeng R, et
421	al. Immunogenicity of the BNT162b2 COVID-19 vaccine as a third dose (booster)
422	following two doses of different primary series regimens in Thailand. Pathog Glob Health
423	2022a:1-3.
424	Wanlapakorn N, Suntronwong N, Phowatthanasathian H, Yorsaeng R, Thongmee T,
425	Vichaiwattana P, et al. Immunogenicity of heterologous inactivated and adenoviral-
426	vectored COVID-19 vaccine: Real-world data. Vaccine 2022b;40(23):32.

428 Figures and Tables

429 **Table 1.** Demographics and baseline characteristics of enrolled participants who received

430 CovovaxTM as a booster dose (total 215 enrolled participants).

	SVC	SPC	AZC	PFC	SAC
Total number	5	50	55	51	54
Sex, Female/total (%)	2/5 (40.0)	21/50 (42.0)	29/55 (52.7)	28/51 (54.9)	23/54 (42.6)
Mean age in year (SD)	46.0 (11.2)	39.3 (12.3)	49.7 (14.6)	42.0 (18.7)	37.7 (13.9)
No comorbidity (%)	3/5 (60.0)	38/50 (76.0)	30/55 (54.5)	32/51 (62.7)	45/54 (83.3)
Underlying diseases (%)					
Allergy	-	-	2/55 (36.4)	1/51 (19.6)	-
Asthma	-	-	2/55 (36.4)	-	-
Cardiovascular diseases	-	1/50 (2.0)	1/55 (18.2)	-	-
Diabetes Mellitus	-	4/50 (8.0)	11/55 (20.0)	10/51 (19.6)	3/54 (5.6)
Dyslipidemia	1/5 (20.0)	4/50 (8.0)	6/55 (7.3)	4/51 (7.8)	2/54 (3.7)
Hypertension	-	8/50 (16.0)	13/55 (23.6)	13/51 (25.5)	8/54 (14.8)
Thyroid diseases	1/5 (20.0)	-	1/55 (18.2)	2/51 (3.9)	-
Other	1/5 (20.0)	1/50 (2.0)	3/55 (5.5)	4/51 (7.8)	3/54 (5.6)
Interval between doses 2 and 3					
Mean (SD)	367.0 (22.3)	236.3 (32.5)	218.9 (37.6)	185.5 (64.8)	235.3 (31.2)
Duration of sample collection					
(days)					
Mean (SD) of visit 2	14.0 (0.7)	14.1 (1.0)	13.8 (1.2)	14.0 (0.9)	13.6 (0.9)
Mean (SD) of visit 3	27.8 (0.5)	28.7 (1.6)	28.0 (1.4)	28.5 (2.0)	28.9 (1.7)

431 *The SVC group has not included for the statistical analysis.

432

434 **Table 2.** Demographic and baseline characteristics of the participants classified using

435 seronegative and seropositive anti-N IgG.

Population 1: Seronegative anti-N IgG participants (n=141)

	SVC*	SPC	AZC	PFC	SAC
Total number	5	31	34	37	34
Sex, Female/total (%)	2/5 (40.0)	14/31 (45.2)	20/34 (58.8)	23/37 (62.1)	11/34 (32.4)
Mean age in year (SD)	46.0 (11.2)	42.6 (13.4)	50.7 (15.4)	42.9 (19.4)	38.9 (13.6)
Interval between doses 2 and 3					
Mean (SD)	367.0 (22.3)	242.7 (32.1)	222.9 (43.6)	184.1 (65.4)	242.4 (287)
Duration of sample collection					
(days)	14.0 (0.7)	14.2 (1.1)	13.7 (1.3)	14.1 (1.0)	13.5 (1.0)
Mean (SD) of visit 2	27.8 (0.5)	28.6 (1.9)	28.1 (1.6)	28.4 (2.0)	29.2 (2.0)
Mean (SD) of visit 3					

Population 2: Seropositive anti-N IgG participants (n=56)

	SVC*	SPC	AZC	PFC	SAC
Total number	0	16	12	10	18
Sex, Female/total (%)	nd	5/16 (31.3)	7/12 (58.3)	4/10 (40.0)	12/18 (66.7)
Mean age in year (SD)	nd	35.1 (8.1)	50.9 (12.0)	41.1 (16.2)	35.9 (14.8)
Interval between doses 2 and 3					
Mean (SD)	nd	224.4 (34.0)	209.9 (24.0)	192.5 (66.2)	219.8 (32.1)
Duration of sample collection					
(days)					
Mean (SD) of visit 2	nd	14.1 (0.9)	14.2 (0.9)	12.2 (4.7)	13.8 (0.4)
Mean (SD) of visit 3	nd	28.8 (1.2)	28.0 (0.4)	25.6 (9.5)	28.4 (0.8)

436 nd – not determined.

437 *The SVC group has not included for the statistical analysis.

438 Six participants who has seroconversion of anti-N IgG after a booster dose were excluded for

analysis.



441

Figure 1. Study flow diagram of participant enrollment, blood sampling, and participant 442 categorization. Participants who were primed with two doses of vaccines included SVC, SPC, 443 AZC, PFC, and SAC at least 3 months after the second dose were enrolled to receive the protein 444 subunit vaccine (CovovaxTM) as a booster dose. Blood samples were collected on days 0, 14 (±7) 445 and 28 (± 7) post booster vaccination. After observation and laboratory testing, the participants 446 were categorized for further analysis according to the anti-N IgG titers. Only seronegative anti-N 447 IgG participants were eligible for evaluation of immunogenicity analyses after booster 448 449 vaccination. The symbol (¶) indicates participants who could not continue the study. The dotted boxes indicate the participants after categorization using anti-N IgG. neg – negative, pos – 450 positive, inf - infection. 451

452

24





455 receiving of a protein subunit vaccine.



Figure 3. anti-RBD Ig/IgG responses of the enrolled participants. Sera samples of SVC, SPC, AZC, PFC, and SAC groups were monitored at 0, 14 and 28 days. (A) anti-RBD Ig (U/mL) and (B) anti-RBD IgG (BAU/mL) of the total enrolled participants. (C) anti-RBD Ig (U/mL) and (D) anti-RBD IgG (BAU/mL) of the seronegative anti-N IgG participants. The lines represent GMTs (95% confidence intervals). The gray area indicates the seronegativity of the anti-RBD Ig (<0.8 U/mL) or anti-RBG IgG (<7.1 BAU/mL). p < 0.05 (*), p < 0.01 (**), p < 0.001 (***).

463

26





Figure 4. Neutralizing activity of participants against the wild type SARS-CoV-2 virus (A) and
BA.2 omicron variant (B). Lines represent the median (interquartile range [IQR]). The gray area
indicates the seronegativity of neutralizing activity of the wild type (<35%) and BA.2 omicron
variant (<30%).

27



470

471 **Figure 5.** Interferon-gamma release assay. Whole blood samples from the participants were

heparinized and then transferred to the Ag3-QFN blood collection tube for 21 hours. The IFN- γ release was monitored by ELISA. Lines represent the median (IQR). *p* <0.05 (*), *p* <0.01 (**), *p*

474 <0.001 (***).

476 Supplementary materials

- 477 **Table S1** Descriptive analysis of laboratory assessments
- 478 **Figure S1.** Local, systemic, and adverse events following different prime vaccination regimens 7
- days after receiving a booster dose. (A) SPC, (B) AZC, (C) PFC, and (D) SAC.
- **Figure S2.** Comparison of individual anti-RBD Ig values stratified by anti-N IgG titers.
- 481 Participants were classified by seronegative and seropositive anti-N IgG (Cut-off \geq 1.4 S/C)
- before a booster dose. (A) SPC, (B) AZC, (C) PFC, (D) SAC regimens. The lines represent
- 483 GMTs (95% confidence interval [CI]). The gray area indicates the seronegativity of the anti-
- 484 RBD Ig (<0.8 U/mL). p <0.05 (*), p <0.001 (***).